CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Cefazolin 3gm for Injection USP and Dextrose Injection USPdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05205486
NCT05205486Phase 1Completed

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of a Single 3 Gram Dose of Cefazolin in Adult Subjects Weighing >= 120 kg Scheduled for Surgery

B. Braun Medical Inc.·interventional·Posted Jan 25, 2022·Updated Feb 28, 2025

In Brief

A Phase 1 clinical trial evaluating Cefazolin 3gm for Injection USP and Dextrose Injection USP for Infections. Completed, enrolled 12 participants across 2 sites.

Detailed Summary

This study is designed to evaluate the pharmacokinetics (PK) of a single 3 gm dose of cefazolin from a DUPLEX container, in adult subjects (weighing \>/= 120 kg) scheduled for surgery. Cefazolin will be administered as a 30-minute intravenous (IV) infusion, per cefazolin Package Insert. Five PK samples per subject will be obtained up to 8 hours after dosing. These data will then be assessed by the validated Cefazolin PK Model to verify there are no significant PK changes within this study population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJan 25, 2022
Enrollment StartApr 5, 2022
Primary CompletionJul 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.4 years ago

Interventions

Cefazolin 3gm for Injection USP and Dextrose Injection USPdrug

Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg